FilingReader Intelligence
North China Pharmaceutical gets drug registration after 1.1bn yuan investment
July 29, 2025 at 09:12 AM UTC•By FilingReader AI
North China Pharmaceutical received a drug registration certificate for its Cobamamide Capsules from the National Medical Products Administration.
The company invested 1.09 billion yuan in developing the product. Twenty-seven companies in China now hold registration certificates for this specific dosage.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:600812•Shanghai Stock Exchange
News Alerts
Get instant email alerts when North China Pharmaceutical publishes news
Free account required • Unsubscribe anytime